Related Experiment Videos
p21 as a prognostic factor in non-small cell lung carcinomas
Mi Seon Kwon1, Young Il Lee, Kyo Young Lee
1Department of Pathology, Dankook University College of Medicine, 16-5 Anseo-dong, Cheonan, Chungnam 330-714, Republic of Korea. m-skwon@hanmail.net
Pathology, Research and Practice
|November 4, 2006
Summary
High p21 expression in non-small cell lung carcinoma (NSCLC) correlates with better patient survival. This finding suggests p21 is a key prognostic factor for NSCLC, aiding treatment decisions.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Non-small cell lung carcinoma (NSCLC) survival rates are influenced by various factors.
- The prognostic significance of p21 expression in NSCLC remains inconsistently reported.
- Further investigation into p21's role in NSCLC patient outcomes is warranted.
Purpose of the Study:
- To evaluate the correlation between p21 expression levels and clinicopathologic characteristics in NSCLC patients.
- To determine the association between p21 expression and patient survival in NSCLC.
- To identify p21 as a potential prognostic biomarker for NSCLC.
Main Methods:
- Analysis of p21 nuclear expression in 90 NSCLC tissue samples.
- Categorization of patients into high and low p21 expression groups based on median percentage.
- Uni- and multivariate analyses to assess survival associations.
Main Results:
- p21 was expressed in all NSCLC cases, with variable immunoreactivity.
- No significant correlation was found between p21 levels and age, gender, histology, grade, or stage.
- High p21 expression was significantly associated with improved survival, particularly in specific subgroups (Stage II/III, males, adenocarcinomas, p53-positive tumors).
Conclusions:
- High p21 expression is an independent prognostic factor for improved survival in NSCLC.
- p21 expression levels may assist in identifying candidates for adjuvant therapies.
- p21 status could guide the selection of appropriate chemotherapeutic agents for NSCLC patients.
